# Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

> **NCT03643107** · PHASE2 · COMPLETED · sponsor: **Allarity Therapeutics** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer Patients

## Interventions

- **DRUG:** Irofulven
- **COMBINATION_PRODUCT:** Prednisolone 10 mg

## Key facts

- **NCT ID:** NCT03643107
- **Lead sponsor:** Allarity Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-17
- **Primary completion:** 2021-10-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-01-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03643107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03643107, "Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03643107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*